Cookies disclaimer

I agree Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.

Regulatory T cell-neutrophil interaction in the development and maintenance of secondary pneumonia (360G-Wellcome-205214_Z_16_Z)

<p>Secondary pneumonia following influenza infection is common, with considerable associated morbidity and mortality. Strikingly, secondary infections tend to arise from bacteria which live otherwise asymptomatically in the oropharynx.&nbsp;</p> <p>Based on existing data, I hypothesise that the development of secondary streptococcal pneumonia is dependent on a key immune-cell molecular pathway, namely Phosphoinsitol-3-Kinase delta (PI3K&delta;), and that inhibition PI3K&delta; will be protective via the following mechanisms.</p> <p>1)&nbsp;&nbsp;&nbsp; Influenza-induced expansion of immunosuppressive regulatory T-cells (T<sub>reg</sub>) which depend on PI3K&delta; for suppressive functioning</p> <p>2)&nbsp;&nbsp;&nbsp; Viral and T<sub>reg</sub> mediated suppression of neutrophil function</p> <p>3)&nbsp;&nbsp;&nbsp; A change in the lung microbiome as a result of the effects 1 and 2, leading to established infection by <em>Streptococcus pneumoniae</em>.</p> <p>&nbsp;</p> <p>The goals are:</p> <p>1) To determin whether PI3K&delta;-null animals are resistant to secondary streptococcal pneumonia.</p> <p>2) To use tools including T<sub>reg</sub> depleted animals, conditional knockout animals and small molecule PI3K&delta; inhibitors to explore mechanisms of resistance.</p> <p>3) To develop a more clinically relevant murine model secondary pneumonia, using a streptococcal colonisation model which when exposed to influenza will develop secondary pneumonia.</p> <p>4) To characterise the respiratory microbiome of animals at various stages will be characterised, looking for factors that may facilitate or militate against development of secondary pneumonia.&nbsp;</p>

£516,560

06 Dec 2016

Grant details
Amount Awarded 516560
Applicant Surname Conway Morris
Approval Committee Clinical Interview Committee
Award Date 2016-12-06T00:00:00+00:00
Financial Year 2016/17
Grant Programme: Title Clinical Research Career Development Fellowship
Internal ID 205214/Z/16/Z
Lead Applicant Dr Andrew Conway Morris
Planned Dates: End Date 2020-09-01T00:00:00+00:00
Planned Dates: Start Date 2017-09-01T00:00:00+00:00
Recipient Org: Country United Kingdom
Region East of England
Sponsor(s) Prof Edwin Chilvers
Additional data added by GrantNav